Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Regulatory and Development Update

January 1, 2026

New Funding Secured for HEALEY ALS Platform Trial

December 22, 2025

Equity Raising Presentation

December 22, 2025

Trading Halt

December 18, 2025

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial

December 11, 2025

Neurizon Completes GMP Tablet Registration Batches

December 3, 2025

Elanco executive appointed as Neurizon's Board Observer

November 26, 2025

Neurizon to present Q1 FY2026 Results

October 30, 2025

Australian Patent Granted for NUZ-001

October 20, 2025

FDA Lifts Clinical Hold on NUZ-001

October 6, 2025

Neurizon Raises $5m via Institutional Placement

September 17, 2025

R&D Tax Incentive Advance & Overseas Finding Approval

September 17, 2025

Appendix 4E and 2025 Annual Report

August 25, 2025

NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE

August 19, 2025

FDA Review Timeline Extended for NUZ-001 IND Clinical Hold

August 15, 2025

Neurizon Secures Loan Against 2025 R&D Tax Rebate

July 29, 2025

Neurizon Submits Clinical Hold Complete Response to FDA

July 24, 2025

Positive feedback from FDA on strategy to lift clinical hold

July 9, 2025

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

July 2, 2025

Neurizon Enters Global Licensing Agreement with Elanco

July 1, 2025

Neurizon develops liquid formulation of NUZ-001

June 25, 2025

NUZ-001 Shows Significant Blood-Brain Barrier Penetration

June 19, 2025

NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease

June 16, 2025

NUZ-001 Shows Promise in a Model of Huntington's Disease

June 15, 2025

Last Patient Successfully Completes Treatment in OLE Study

May 4, 2025

NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells

April 4, 2025

NUZ-001 Shows Positive Results in Human 3D Brain Model

March 31, 2025

NUZ-001 shows promising respiratory outcome

March 23, 2025

Neurizon Commences Initiatives to Lift Clinical Hold

March 16, 2025

Appendix 4D - Half-year Financial Report - 31 December 2024

February 17, 2025

FDA Guidance on NUZ-001 IND Application

February 16, 2025

US Patent granted for NUZ-001

February 4, 2025

Neurizon updates on NUZ-001 IND Application

January 16, 2025

Neurizon Files IND Application to Support HEALEY ALS Trial

December 17, 2024

Neurizon Granted OMPD for NUZ-001 in Europe

December 16, 2024

Positive 8-month Interim Data from OLE Study

December 15, 2024

Neurizon Receives Additional R&D Tax Incentive Rebate

December 11, 2024

Neurizon Presents Positive Preclinical Data on NUZ-001

November 14, 2024

NUZ-001 Reduces Aggregation of Key ALS Disease Target

November 14, 2024

Positive opinion received on OMPD for NUZ-001 in Europe

November 10, 2024

PharmAust Receives R&D Tax Incentive Rebate

October 8, 2024

Appendix 4E and 2024 Annual Report

August 30, 2024

Positive Interim Study Results from OLE Study in ALS

August 25, 2024

PharmAust Completes Share Purchase Plan

July 23, 2024

Monepantel Selected for Entry into HEALEY ALS Platform Trial

July 14, 2024

Share Purchase Plan Offer Booklet

June 27, 2024

PharmAust raises $10 million via Placement and announces SPP

June 20, 2024

OLE Study update reveals impressive Survival Data

June 4, 2024

Executive team strengthened, appointment of MD/CEO & new CSO

May 30, 2024

PharmAust receives Orphan Drug Designation for monepantel

May 17, 2024

← Newer news releases · Older news releases →

Decks

The 5 newest of 36 decks. Every deck is listed under its year.